Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
Acquired constitutive activation of protein tyrosine kinases is a central feature in the pathogenesis of chronic myeloproliferative disorders (CMPDs). The most commonly involved genes are the receptor tyrosine kinases PDGFRA, PDGFRB, FGFR1 or c-KIT and the non-receptor tyrosine kinases JAK2 and ABL. Activation occurs as a consequence of specific point mutations or fusion genes generated by chromosomal translocations, insertions or deletions. Mutant kinases are constitutively active in the absence of the natural ligands resulting in deregulation of haemopoiesis in a manner analogous to BCR-ABL in chronic myeloid leukaemia. With the advent of targeted signal transduction therapy with tyrosine kinase inhibitors, an accurate diagnosis of CMPDs by morphology, karyotyping and molecular genetics has become increasingly important. Imatinib induces high response rates in patients associated with constitutive activation of ABL, PDGFRalpha, PDGFRbeta and some KIT mutants. Other inhibitors under development are promising candidates for effective treatment of patients with constitutive activation of JAK2, FGFR1 and imatinib-resistant KIT mutants.
enzyme activation, mutation, review, genes, humans, treatment, patients, protein-tyrosine kinase, tyrosine, genetics, protein-tyrosine kinases, karyotyping, protein kinase inhibitors, diagnosis
205-216
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
2007
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Reiter, Andreas, Walz, Christoph and Cross, Nicholas C.P.
(2007)
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
Current Drug Targets, 8 (2), .
Abstract
Acquired constitutive activation of protein tyrosine kinases is a central feature in the pathogenesis of chronic myeloproliferative disorders (CMPDs). The most commonly involved genes are the receptor tyrosine kinases PDGFRA, PDGFRB, FGFR1 or c-KIT and the non-receptor tyrosine kinases JAK2 and ABL. Activation occurs as a consequence of specific point mutations or fusion genes generated by chromosomal translocations, insertions or deletions. Mutant kinases are constitutively active in the absence of the natural ligands resulting in deregulation of haemopoiesis in a manner analogous to BCR-ABL in chronic myeloid leukaemia. With the advent of targeted signal transduction therapy with tyrosine kinase inhibitors, an accurate diagnosis of CMPDs by morphology, karyotyping and molecular genetics has become increasingly important. Imatinib induces high response rates in patients associated with constitutive activation of ABL, PDGFRalpha, PDGFRbeta and some KIT mutants. Other inhibitors under development are promising candidates for effective treatment of patients with constitutive activation of JAK2, FGFR1 and imatinib-resistant KIT mutants.
This record has no associated files available for download.
More information
Published date: 2007
Keywords:
enzyme activation, mutation, review, genes, humans, treatment, patients, protein-tyrosine kinase, tyrosine, genetics, protein-tyrosine kinases, karyotyping, protein kinase inhibitors, diagnosis
Identifiers
Local EPrints ID: 60157
URI: http://eprints.soton.ac.uk/id/eprint/60157
ISSN: 1389-4501
PURE UUID: cd7ab906-bb35-44c9-a335-bbf9b18f5b5b
Catalogue record
Date deposited: 05 Sep 2008
Last modified: 09 Jan 2022 03:08
Export record
Contributors
Author:
Andreas Reiter
Author:
Christoph Walz
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics